[1] van Wyk HC, Park JH, Edwards J, et al. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer[J]. Br J Cancer,2016,115(2):156-163. [2] Wu H, Reynolds AB, Kanner SB, et al.Identification and characterization of a novel cytoskeleton-associated pp60src substrate[J]. Mol Cell Biol,1991,11(10):5113-5124. [3] Cai JH, Zhao R, Zhu JW, et al.Expression of cortactin correlates with a poor prognosis in patients with stages Ⅱ-Ⅲ colorectal adenocarcinoma[J]. J Gastrointest Surg,2010,14(8):1248-1257. [4] 朱建伟, 陆毅样, 赵任, 等. 皮层蛋白氨基端同源性多肽分子对大肠癌细胞迁移、内吞能力及侵袭性的抑制[J]. 世界华人消化杂志,2009,17(32):3302-3306. [5] Edge SB, Byrd DR, Compton CC, et al.AJCC Cancer staging manual[M]. 7th ed. New York:Springer,2010. [6] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132. [7] Wang R, Wang MJ, Ping J.Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: A population-based cohort study of SEER 9 registries data(1988-2011)[J]. Medicine (Baltimore),2015,94(35):e1402. [8] Graham RP, Vierkant RA, Tillmans LS, et al.Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort[J]. Am J Surg Pathol,2015,39(10):1340-1346. [9] Caie PD, Turnbull AK, Farrington SM, et al.Quantification of tumour budding, lymphatic vessel density and invasion through image analysis in colorectal cancer[J]. J Transl Med,2014,12:156-168. [10] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31. [11] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31. [12] Pollard TD, Borisy GG.Cellular motility driven by assembly and disassembly of actin filaments[J]. Cell,2003, 112(4):453-465. [13] Bryce NS, Clark ES, Leysath JL, et al.Cortactin promotes cell motility by enhancing lamellipodial persistence[J]. Curr Biol,2005,15(14):1276-1285. [14] Mueller SC, Yeh Y, Chen WT.Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells[J]. J Cell Biol,1992,119(5):1309-1325. [15] Mizutani K, Miki H, He H, et al.Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts[J]. Cancer Res,2002,62(3):669-674. [16] Zhang X, Liu K, Zhang T, et al.Cortactin promotes co-lorectal cancer cell proliferation by activating the EGFR-MAPK pathway[J]. Oncotarget,2017,8(1):1541-1554. [17] Prall F, Nizze H, Barten M.Tumour budding as prognostic factor in stage Ⅰ/Ⅱ colorectal carcinoma[J]. Histopa-thology,2005,47(1):17-24. [18] Prall F, Weirich V, Ostwald C.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC) gene[J]. Histopa-thology,2007,50(3):318-330. [19] Jass JR, Barker M, Fraser L, et al.APC mutation and tumour budding in colorectal cancer[J]. J Clin Pathol,2003,56(1):69-73. [20] Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, et al.Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma[J]. Hum Pathol,2012,43(7):1094-102. [21] Brabletz T, Hlubek F, Spaderna S, et al.Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin[J]. Cells Tissues Organs,2005,179(1-2):56-65. [22] Markl B, Hardt J, Franz S, et al.Tumor budding, uPA, and PAI-1 in colorectal cancer: update of a prospective study[J]. Gastroenterol Res Pract,2017,2017:6504960. |